NCT07113834

Characteristics of Ankylosing Spondylitis Associated Uveitis

Characteristics of Ankylosing Spondylitis Associated Uveitis: A Retrospective Study in Egyptian Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 22 (actual)
• Sponsor: Benha University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This study aims to understand the clinical characteristics associated with AAU in Egyptian AS patients, and the prognostic factors, in terms of the Corrected Distance Visual Acuity (CDVA).

Detailed description

This is a one-year retrospective cohort study conducted at the Spine and Ophthalmology Clinics of Benha University - Faculty of Medicine, Egypt, between September 2023 and August 2024. The study aims to characterize the clinical features and identify prognostic factors affecting visual outcomes in patients with Ankylosing Spondylitis-associated Anterior Uveitis (ASAAU). Patients included in this study were Egyptian nationals who initially presented to the Spine Clinic with systemic symptoms of ankylosing spondylitis (AS) and were subsequently referred to the Ophthalmology Clinic due to ophthalmic complaints. Only patients who were confirmed to have both AS (diagnosed according to the Modified New York criteria and radiographic imaging) and anterior uveitis (confirmed by slit-lamp examination and supported by Optical Coherence Tomography \[OCT\] and Fluorescein Angiography \[FA\]) were enrolled. The final sample included 26 eyes from 22 patients who fulfilled the inclusion criteria. Patients were excluded if they were non-Egyptian, had other systemic autoimmune or immunologic conditions, had uveitis due to secondary causes, had undergone ocular surgeries, did not receive uveitis treatment, were lost to follow-up, or had incomplete medical records.

Conditions

• Uveitis

Interventions

Type	Name	Description
DRUG	Adalimumab	A tumor necrosis factor-alpha (TNF-α) inhibitor used as a biologic agent for the treatment of ankylosing spondylitis. Administered subcutaneously as part of systemic immunomodulatory therapy.
DRUG	Systemic corticosteroids	Oral or intravenous corticosteroids (e.g., prednisolone) used to suppress systemic inflammation in cases of active AS or severe uveitis.

Timeline

• Start date: 2023-09-01
• Primary completion: 2023-09-01
• Completion: 2024-08-01
• First posted: 2025-08-11
• Last updated: 2025-08-11

Locations

1 site across 1 country: Egypt